Apogee Therapeutics, Inc.
corporate_fare Company Profile
Apogee Therapeutics, Inc. (NASDAQ:APGE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 37 items for APGE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-03, rated 9/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 19 rated 8 or above. Recent SEC coverage for APGE spans 8-K, 10-Q, DEFA14A, DEFM14A.
Recent high-impact activity:
- AbbVie Completes $10.9B Acquisition of Apogee; APGE to Delist September 4
- Apogee Stockholders Overwhelmingly Approve $10.9B AbbVie Acquisition; All Directors to Resign at Close
- Q2 Report Confirms AbbVie Merger Progress, Strong Cash Position, Positive Clinical Data
- Apogee Q2 2026: $1.3B Cash, Pipeline Advances Ahead of AbbVie Vote
- Key regulatory hurdles cleared for Apogee's merger with AbbVie, with HSR, German, and Austrian approvals secured ahead of the August 11 vote
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for APGE, detected from its recent SEC filings · based on capital-structure filings through 2026-03-25.
Public Offering Priced · Net Proceeds to Company
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →